Back to News
Market Impact: 0.15
Processa Pharmaceuticals, Inc. Appoints Dr. Sheila Gujrathi as Executive Chair and Announces FDA Clearance of Phase 2 IND for VT-7208
Source: Nasdaq
Management & Governance
Justin Yorke resigned as chair of Processa Pharmaceuticals’ board on October 27, 2026. The board appointed Dr. Sheila Gujrathi as non-employee executive chair effective October 28; the article text ends before completing its statement about Yorke’s next role.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Norwegian shares surge 13% on earnings beat, guidance raise
- ECB’s Lagarde Steps Aside as European Economic Pressure Builds
- Walmart investigates Flipkart over employee kickback claims: Moneycontrol
- Thrive Holdings to acquire ADT for $7.6 billion in cash deal
- Alphabet Miss Revives AI Fears
- Norwegian Cruise Line stock jumps on earnings beat